Exalenz Receives FDA Approval

August 3, 2015 | Exalenz, the Israeli company that develops devices for detecting gastrointestinal and liver conditions, announced that it received FDA approval in a joint clinical trial with Galectin Therapeutics. Exalenz’s product, the BreathID, will be used in a second-stage clinical trial for an experimental treatment for fatty liver disease. Exalenz is headed by CEO Raffi Werner.